SLC2A1 and metabolic syndrome: A number of these have been developed for obesity, dyslipidemias, and diabetes, and may find use for Glut1 DS too.60 Similarly, small molecules that alter one or more of the signaling pathways identified here could become a means of enhancing Glut1 expression for the treatment of haploinsufficient Glut1 DS.